Danish biotech start-up Fuse Vectors has launched its R&D operations in Leiden. From its new base at the Leiden Bio Science Park, the company is set to accelerate the development of innovative gene therapies
Fuse Vectors is pushing the boundaries of gene therapy through its novel cell-free AAV production platform. By eliminating the reliance on traditional cell-based systems, the company’s technology enables faster, scalable and more consistent production of viral vectors. With its Leiden site, Fuse Vectors is building a platform that supports projects ranging from early discovery to advanced clinical development.
Fuse Vectors chose to establish in this region because it offers an ideal ecosystem for continued growth. Having successfully passed the proof-of-concept stage, the company is now focused on applying its technology in drug development and production.
“This region provides an exceptional environment for this next step, with highly skilled talent, specialized services and strong potential partners in both pre-clinical and clinical-stage AAV development.” -Benjamin Blaha Co Founder, Co-CEO and CTO of Fuse Vectors
Fuse Vectors is actively contributing to the Leiden region’s life sciences & health ecosystem through its innovative cell-free AAV technology. This unique approach has the potential to make a significant impact on the development of future gene therapies. The company continues to explore new partnerships and opportunities that will help accelerate the creation of transformative AAV-based treatments for patients around the world.
Fuse Vectors’ expansion into Leiden was supported by the Netherlands Foreign Investment Agency (NFIA) and InnovationQuarter, both partners in the Invest in Holland network. This dynamic network empowers international companies to successfully expand into the Dutch market, offering a seamless soft landing and direct access to a thriving innovation ecosystem to help them grow faster and collaborate more effectively.
“We’re thrilled to welcome Fuse Vectors to Leiden. Their unique technology strengthens our region’s expertise in gene therapy and perfectly aligns with the innovative and collaborative spirit that defines South Holland’s life sciences & health community.”– Daniël Bruning, Account
Leiden Bio Science Park welcomes Eli Lilly, strengthening The Netherlands' position in life sciences with a $3 billion facility. Eli Lilly and Company announced plans to build a...
From the Van Nelle Factory to BioPartner 5, from heritage to future, from start-up to innovative lab design agency. After an inspiring and innovative seven-year start at the...
Starting Friday, November 14 at 4:00 p.m., two temporary closures (in place for the duration of the Plesmanlaan project, until approximately Q3 2027) will be implemented for...